Replies to post #26372 on ViaDerma Inc (VDRM)

[retired early]

If this is what they call new math these days $4.5 would be nice.

[zombywolf]

Billy Boy, need to fix your numbers (to be real).

There are about 380MM shares out (you have been gone a little while). So your $31MM net needs to be divided by 380MM to get .082
not .15- .082 x 30PE= $2.46 per share. Still OK for me.

[hlsh]

Hey 2dollarbill , when you have a moment , come on over to the ONCI board & help figure our P.E. Ratios-Target price , many thxs ahead //// seems like you know what ur doing.... thxs again / HLSH

[trademax42]

hey 2dollarbill...nice analysis, thank you.

I have a question though: how or where from you get a PE ratio of 30 for your analysis?

62.5m in gross sales with a $31m in net sales which divided by outstanding stock = 0.15 cents earnings X 30x earnings (pe - price to earnings) = $4.50 + target

Two links below present PE ratios for industry sectors including biotechnology. The Stern School of Business shows a forward PE ratio of 110 based on 426 firms and data used as of January 2017 (current and trailing PE being even higher). Look for Drugs (biotechnology) in the link:

http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/pedata.html

The next one is from Yahoo Finance, it provides PE ratios for 17 biotech companies. I added up the PE ratios for all 17 companies and took a simple average of the total, and came up with a PE ratio significantly higher than 30, if my math is correct (I didn't include Exelixis Inc., the PE ratio being too high).

https://finance.yahoo.com/screener/predefined/biotechnology/?offset=0&count=25

My two cents FWIW.


Go $$VDRM$$

Disclosure: My posts are just my opinion, not intended for investment advice. I am often wrong, hence do your own DD.